Coronavirus Drug Shows Global Hurdles To Patent Protection
Recently, Gilead Sciences Inc. developed a nucleotide analog prodrug, Remdesivir, also known as GS-5734, as a treatment for Ebola virus and other pathogenic infections.[1] It was subsequently found that Remdesivir also...To view the full article, register now.
Already a subscriber? Click here to view full article